Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. [electronic resource]
Producer: 20200721Description: 98-101 p. digitalISSN:- 1872-8332
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents, Immunological -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- B7-H1 Antigen -- antagonists & inhibitors
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cost-Benefit Analysis
- Female
- Health Care Costs
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Markov Chains
- Molecular Targeted Therapy
- Prognosis
- Propensity Score
- Quality of Life
- Randomized Controlled Trials as Topic
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.